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 Systemic sclerosis is the most severe disease within the 
scleroderma spectrum and is a major medical challenge with 
high mortality and morbidity. There have been advances 
in understanding of pathogenesis that reﬂ ect the interplay 
between immune-inﬂ ammatory processes and vasculopathy 
and ﬁ brosis. It can be regarded as a disease of connective 
tissue repair and this leads to organ-based complications. 
However the aetiology and triggering events remain to be 
elucidated. Treatment is available for many aspects of the 
disease although the available therapies are not curative 
and some complications remain very challenging, especially 
non-lethal manifestations such as fatigue, calcinosis and 
anorectal dysfunction. Immunosuppression is now established 
as a beneﬁ cial approach but balancing risk and beneﬁ t is vital, 
especially for powerful approaches such as autologous stem 
cell transplantation. 
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 Introduction 
 Systemic sclerosis (SSc) is an autoimmune rheumatic disease 
with high case-specific mortality. More than half those 
diagnosed with SSc eventually die as a direct result of the 
disease. Moreover, in addition to high mortality from internal 
organ disease there is also a very substantial non-lethal burden 
that impacts on function, quality of life and causes a range of 
severe and disabling symptoms. 
 The range of organ-based complications is shown in Fig  1 . 
These occur at different time and frequency in the two major 
subsets of SSc, limited and diffuse disease. The timing and 
frequency of major heart, lung or kidney involvement has 
recently been defined in a large single-centre cohort. 1 This 
is helpful in defining the risk of each of these important 
manifestations. The clinical heterogeneity of SSc is important 
since it determines the appropriate approach to treatment. An 
overview of treatment approaches is given in  Fig 2. 
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 Over the past few years there have been substantial advances 
in the understanding of SSc and also in the assessment and 
management of the disease. Overall survival has improved and 
this probably reflects earlier detection of major complications, 
as well as a more proactive approach to management of the 
condition.  1 
 Current paradigm for SSc pathogenesis 
 It is now appreciated that SSc is an autoimmune disease and 
shares much in common with other similar conditions. There 
is activation of the innate and adaptive immune systems. A 
range of disease specific autoantibodies are important for 
diagnosis and help to stratify distinct patient groups. Vascular 
manifestations are associated with the immunoinflammatory 
aspects of the disease; these include microvascular 
abnormalities, with activation of endothelial cells and 
macrovascular changes, including proliferative vasculopathy. 
In addition, a propensity to cold or stress-induced vasospasm 
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 Fig 1.  Pathology and clinical impact of SSc. The hallmark pathologies of 
ﬁ brosis, inﬂ ammation and vasculopathy in SSc translate into a challenging 
array of organ-based complications that deﬁ ne the burden and impact of 
disease. Highlighted in red are those aspects that contribute to high case-
speciﬁ c mortality, mostly due to cardiorespiratory manifestations. SSc = 
systemic sclerosis . 
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is typical in SSc and manifests as Raynaud's phenomenon. This 
is a common finding in other autoimmune rheumatic diseases 
and also in otherwise healthy individuals, when it is termed 
primary Raynaud's phenomenon. 2 
 It is notable that recent genetic studies of SSc have identified 
a number of loci associated with the disease or with subsets or 
complications. 3 Association with antinuclear antibody (ANA)-
based subgroups have consistently been more reproducible 
than those for non-immune genetic loci across different 
patient cohorts. Many of these loci are relevant to innate 
immune system function although some may reflect altered 
connective tissue synthesis or remodelling, such as a reported 
polymorphism in the connective tissue growth factor promoter 
associated with SSc. 4 
 An emerging model of pathogenesis is that SSc represents a 
susceptibility phenotype to excessive fibroproliferative response 
to tissue injury or damage that may be modulated or driven 
by the immune response, but appears to become sustained 
and independent of significant ongoing inflammation. 5 The 
differing extents of skin disease that define major SSc subsets 
could be determined by host factors, and the pattern of internal 
organ disease may reflect costimuli or other factors. This 
model fits especially for complications such as scleroderma 
renal crisis (SRC) or pulmonary arterial hypertension, where 
only a minority of cases are affected and there is a clear 
temporal element to risk. This is exemplified by recent studies 
confirming the association between malignancy and SSc in 
some cases, 6 suggesting shared pathogenic factors or a link with 
autoimmunity. 7 Thus, SRC seems to develop mostly within 
three years of disease onset, but in later stage disease is very 
rare, suggesting that the majority of SSc cases may be protected 
from SRC. Pulmonary hypertension (PAH ) develops in 1–2% 
of SSc cases per year from three years of disease duration; this 
risk persists with prevalence at approximately 5% at 5 years, 
10% at 10 years and 15% at 15 years. 8 Recent animal model 
studies 9,10 have better defined the potential mechanisms for 
the association in PAH, revealing that SSc may represent a 
phenocopy of bone morphogenetic protein receptor type II 
(BMPRII) deficiency that reflects transforming growth factor 
beta induced promotion of BMPRII protein degradation. 11 
 Better understanding of the pathogenesis of SSc also has 
unravelled likely pathways and mediators that could drive the 
disease. Some of the pathways and mediators are summarised 
in Fig  3 . Improved understanding of the pathogenesis of SSc is 
important since some of these pathways may be amenable to 
therapeutic modulation. 
 Classiﬁcation and subsets of SSc 
 Traditional classification of SSc has depended on the extent 
of skin sclerosis. This defines cases of diffuse or limited 
disease. Other relevant subsets include cases labelled as SSc 
sine scleroderma. These are patients that manifest SSc-related 
internal organ disease, Raynaud's phenomenon and have 
typical ANA reactivity but lack skin sclerosis. Such cases are 
likely to often be diagnosed as organ-specific conditions, such 
as idiopathic lung fibrosis, PAH or primary gut dysmotility 
syndromes. It is important to recognise these cases as 
additional investigation, and management may be necessary. 
Another important group are those cases of SSc with overlap 
connective tissue disease (CTD). These may include some 
cases of mixed CTD although this disease has more defined 
classification criteria. Up to one-fifth of cases of SSc will have 
features of arthritis, lupus or myositis, and these cases need to 
receive treatment for the overlap manifestations as well as SSc. 
 The classification criteria for SSc were updated in 2013 
and the new criteria 12 are proving substantially more robust 
that previous American Rheumatism Association (ARA) 
preliminary criteria. 13 The new system reflects contemporary 
assessment and investigation of SSc. The current classification 
criteria are listed below and for a definite case to be identified 
at least 9 points are required. It should be noted that all cases 
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 Fig 2.  Overview of management 
of SSc. Patients with a conﬁ rmed 
diagnosis of SSc are classiﬁ ed 
into diffuse or limited subsets 
and this determines the main 
focus of therapy although around 
one ﬁ fth of cases have overlap 
features of another concurrent 
autoimmune rheumatic disease. 
In all cases vigilant follow up to 
identify major complications and 
general symptomatic approaches 
are cornerstones of modern 
management. dc = diffuse systemic 
sclerosis; GI = gastrointestinal; 
lcSSc = limited systemic sclerosis; 
SSc = systemic sclerosis. 
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that fulfil the older ARA criteria are within this new system, 
however it is designed to be more sensitive for cases with 
organ-based pathology or limited disease. It is important to 
clarify that the classification criteria are not sensitive enough 
to confirm diagnosis in all cases and also that they do not 
apply when there is an alternative medical condition, such as 
another autoimmune rheumatic disease, that better explains 
the observed clinical features. 
 Utilising autoantibody patterns in SSc classiﬁcation 
 One of the strongest signals of autoimmunity being relevant 
to SSc is the association of high-titre SSc patterns of ANA 
reactivity, which point towards specific alterations in the 
adaptive immune system. These include several SSc-specific 
reactivities and these are generally mutually exclusive. This 
has allowed association studies to define the risk of specific 
complications, and these associations are useful in clinical 
practice, especially as their hallmark SSc antibody is usually 
present at time of diagnosis and this remains constant during 
follow up. Specific clinical associations are listed in Table  1 and 
these are generally independent of disease subset. In this way, 
the ANA patterns provide an alternative and complementary 
subgrouping for SSc that is clinically relevant. Interestingly, 
many of the genetic associations with SSc, especially those 
relating to immunogenetics, are strongly associated with 
ANA subtypes. This may reflect the defined MHC class II 
associations for individual ANAs that likely determine the 
immunoreactivity to relevant target epitopes. Ultimately, this 
may inform therapeutic advances. 14 
 Disease-modifying treatment 
 Although there is no curative therapy for SSc, there has been 
substantial progress in treatment over the past decades. This 
includes better evidence to support standard approaches to 
treat the immune and vascular aspects of SSc. There are no 
proven antifibrotic treatments, although potential therapies are 
emerging and under evaluation. It is encouraging, by analogy, 
that two agents have recently been licensed for treatment of 
lung fibrosis in IPF. Otherwise, the majority of therapeutic 
advances in SSc have come from better identification and 
management of specific organ-based complications. 
 Broad spectrum immunosuppression 
 A number of trials have now confirmed benefit from 
immunosuppression, demonstrating improvement in 
skin or stabilisation of lung function using agents such as 
cyclophosphamide or methotrexate. The best current evidence 
for effectiveness of a broad spectrum approach comes from 
emerging data in high-intensity immunosuppression with 
autologous haemopoietic stem cell transplantation. Two trials 
are published, the small ASSIST study from the USA 15 and 
a much larger ASTIS trial led from Europe. 16 A third study, 
SCOT, is North American and has fully recruited and is 
ongoing. 17 The most complete dataset so far is ASTIS. This 
study suggested improved long-term survival and event-free 
survival after autologous stem cell transplant, compared 
with a control arm receiving intravenous cyclophosphamide. 
However, survival advantage was not seen until two years after 
transplant and a 10% transplant-related mortality (TRM) was 
reported. Improvement in secondary end-points, such as skin, 
offered more robust evidence of benefit. However, this remains 
a challenging study to translate into practice due to the high 
TRM and the need to exclude candidates at very high risk of 
cardiopulmonary disease due to unacceptable mortality. Less 
toxic treatment approaches and better case selection methods 
will be important to progress in this field. Nevertheless, the 
ongoing studies, in particular ASTIS, have been landmarks in 
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 Fig 3.  Disease mechanism in SSc: 
linking pathogenesis to therapeutic 
targets. Studies of patient samples, 
genetics and animal models have 
deﬁ ned likely processes that determine 
the pathogenesis of SSc. Within these 
pathways there are candidate mediators 
that may be targeted in future 
therapeutic trials. Some of these such 
as endothelin axis and IL6 are already in 
the clinical arena . 
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the field of SSc treatment and provide a robust platform for 
future progress. 
 Although less robust than a prospective controlled trial 
design, observational and cohort studies have emerged that 
suggest benefit from currently used immunosuppressive 
drugs. The UK observational study suggested improvement 
with all three of the agents in common use for skin fibrosis, 
methotrexate (MTX), mycophenolate mofetil (MMF) and 
cyclophosphamide. 18 However, it was not sufficiently powered 
to discriminate between these agents. A large European 
observational trial in early diffuse SSc is underway 19 and may 
provide important information. Analysis of small controlled 
trials of MTX and cohort studies of MMF are also supportive 
of benefit for these agents in SSc and this has been incorporated 
into the current European League Against Rheumatism 
treatment recommendations. 20 
 Vascular therapies 
 SSc is as much a vascular disease, as a fibrotic process and all 
patients should be considered for treatment of vasculopathy. 
This includes treatment of secondary Raynaud's phenomenon, 
as well as the complications of digital vasculopathy, including 
digital ulceration and gangrene. A multifaceted approach is 
needed that includes multidisciplinary input to optimally 
manage digital vascular disease. Other vascular complications, 
such as pulmonary arterial hypertension or scleroderma 
renal crisis, occur less often but are treatable; management is 
discussed further below. 21 
 Management of organ-based disease 
 Lung ﬁ brosis 
 Management of lung fibrosis requires careful assessment. Serial 
pulmonary function testing and definition of the extent of 
disease by lung computerised tomography (CT) scan provide 
the cornerstone of management. A simple staging system has 
been developed and validated in several independent cohorts. 
This offers a practical tool for identifying cases that are at 
greatest risk of progression to severe lung fibrosis and that 
should be treated with more intensive immunosuppression. 
The evidence base for using cyclophosphamide in lung fibrosis 
comes from two clinical trials. The US study, SLS1, suggested 
statistical benefit at 12 months for oral cyclophosphamide 
compared with placebo; however this benefit was very 
marginal. Benefit was maximal at 18 months after starting 
therapy and was particularly apparent in cases with more 
extensive disease on CT scan. 22,23 The UK trial of intravenous 
cyclophosphamide suggested similar treatment effect, albeit 
as a strong trend, after 6 months of intravenous therapy 
followed by oral azathioprine. 24 The SLS2 trial is underway 
to compare MMF with oral cyclophosphamide. In relation to 
skin disease, there is an emerging evidence base from small 
trials and cohort analysis supporting MMF use. Rituximab has 
also been used as a therapy for severe lung fibrosis and will be 
tested in prospective clinical trials that are planned or ongoing. 
At present, rituximab is reserved for use in cases that have 
failed to respond adequately to standard immunosuppression. 
Management of oesophageal reflux is important in SSc 
 Table 1.  Summary of patterns of ANA reactivity and clinical and genetic associations in systemic sclerosis. 
Target antigen Frequency, % Staining pattern Clinical association Genetic association* 
Centromere 15–40 Kinetochore lcSSc, PAH HLA-DQB1
TNF-863A
GRB10
NOTCH4
Topoisomerase-1 (Scl70) 10–40 Speckled dcSSc, lung fibrosis HLA-DPA1/B1
HLA-DPB2
HLA-DRB1
RNA polymerase III 4–25 Fine speckled/nucleolar Renal crisis, malignancy, PAH HLA-DRB1
HLA-DRB3
HLA-DRB4
HLA-DQB4
EDNRA
Fibrillarin (U3RNP) 1–5 Nucleolar/coilin PAH, cardiac, myositis HLA-DQB1
Pm-Scl 3–6 Nucleolar Myositis overlap None reported
U1RNP 5–35 Speckled Overlap features HLA-DRB1
HLA-DPB1
Th-To 1–7 Nucleolar lcSSc, PAH, lung fibrosis None reported
U11/U12 1–5 Nucleolar Lung fibrosis None reported
 *the table summarises reported associations that may differ between ethnic and geographically defined populations but are consistently seen for HLA region and 
specific ANA patterns suggesting that there is a genetic basis to the development of SSc-associated autoantibodies.  ANA = antinuclear antibodies; dcSSc = diffuse 
systemic sclerosis; HLA = human leukocyte antigen; lcSSc = limited systemic sclerosis; PAH = pulmonary arterial hypertension. 
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to minimise risk of aspiration-associated lung damage. 
Antioxidant agents, including N-acetyl cysteine, are plausible 
and often used in progressive disease. The utilisation of recently 
licensed IPF drugs, such as pirfenidone and nintedanib, 
remains uncertain but will hopefully be addressed in future 
clinical trials. 
 Pulmonary hypertension 
 Diagnosis of PAH can only be made by right heart catheter. 25 
It occurs in 1–2% of SSc cases per year and this risk appears 
to persist throughout the disease. It is therefore an important 
complication that may occur in up to 15% of cases. 8 It most 
often reflects precapillary PAH and is treatable using licensed 
therapies for group I PAH. In SSc-associated PAH treatments 
are available as a result of CTD-PAH subjects being included 
in all the pivotal trials that have led to licensing of current 
treatments. 26 Generally a drug targeting the nitric oxide 
pathway is used or an endothelin receptor antagonist; later, 
these oral agents are often given in combination. Prostanoid 
therapy is mostly given to more advanced or progressive cases 
since administration is more challenging. In SSc, approximately 
one-third of PH is due to associated cardiac disease I (group 
II postcapillary PH) or severe lung fibrosis with hypoxia 
(group III PAH). Lung fibrosis and PAH often co-exist making 
management challenging. Therefore, expert assessment is 
needed to determine whether there is a PAH component that 
may be amenable to treatment. 27 
 Scleroderma renal crisis 
 SRC is treatable using angiotensin-converting-enzyme 
inhibitors and these have transformed outcomes. 28 Awareness 
of risk and patient education are important and enable SRC to 
be diagnosed as soon as possible. Early diagnosis is associated 
with better long-term outcomes in terms of renal recovery 
and survival. Since renal recovery may occur up to two years 
after SRC, decisions about renal transplantation should be 
delayed until this time, although allografting is certainly a 
benefit for patients on long-term dialysis and associated with 
improved survival and quality of life. 29 Recurrent renal crisis 
in the allograft is very rare and this may reflect the obligate 
immunosuppression used in this context after grafting that 
may also treat the underlying SSc. 30 
 Gastrointestinal complications 
 The commonest internal organ complication of SSc is 
involvement of the gastrointestinal tract. 31 Almost all patients 
have troublesome gastro–oesophageal reflux but this generally 
responds well to treatment with acid suppressive drugs, 
especially proton pump inhibitors. These may be needed as long-
term therapy and administered at higher doses than in general 
medical practice. A combination of protein-pump inhibitors and 
H 2 antagonists may give additional symptom relief. Additional 
common gut complications in SSc include constipation, 
anorectal incontinence and small intestinal overgrowth. The 
latter may be treated using broad spectrum antibiotics. 32 In a 
minority of cases, intestinal failure occurs and there is a growing 
experience of using parenteral nutrition at home to improve the 
outcome of this subgroup of SSc cases.  33 
 Other difﬁ cult aspects of disease 
 There are many aspects of SSc that remain challenging to 
patients and are hard to treat. This includes severe pruritus, 
calcinosis, fatigue, and the impact on facial appearance 
and musculoskeletal function. The non-lethal burden of 
SSc is becoming more important as survival improves as a 
result of better management of some of the life-threatening 
complications. Therefore, the challenge of SSc is likely to 
remain despite advances in management that are occurring. 34 
 Conclusions 
 SSc is a heterogeneous disease and the diverse patterns of clinical 
involvement require an individualised approach to management. 
Subsetting and staging the disease is important but more 
specific risk stratification is also needed. As discussed, ANA 
pattern can be used to predict risk of specific complications, in 
particular lung fibrosis (anti-topoisomerase-1) or SRC (anti-RNA 
polymerase). Composite scores to predict PAH development 
(DETECT and others) and also lung fibrosis and survival 8,35–37 
are also emerging. These scores often integrate multiple clinical 
and laboratory features and, once validated, offer potential for 
a stratified approach to treatment that may further improve 
outcome. ■ 
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